Incidence and predictors of hypoglycaemia in type 2 diabetes - an analysis of the prospective DiaRegis registry

BMC Endocrine Disorders

Volumn 12, Issue , 2012, Pages

  Tschöpe, Diethelm ^a,b   Bramlage, Peter ^c   Binz, Christiane ^d   Krekler, Michael ^d   Deeg, Evelin ^e   Gitt, Anselm K ^e,f  

^a Stiftung Der herzkranke Diabetiker in der Deutschen Diabetes Stiftung   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Institut fur Pharmakologie und Praventive Medizin   (Germany)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; AMPUTATION; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DATA ANALYSIS; DEPRESSION; DIABETIC RETINOPATHY; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; SMOKING;

EID: 84872376142     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-12-23     Document Type: Article

References (43)

1. Cox D, Gonder-Frederick L, McCall A, Kovatchev B, Clarke W. The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes. Int J Clin Pract Suppl 2002, 129:20-26.
2. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139. 10.1056/NEJMoa0808431, 19092145.
3. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
4. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
5. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008, 358(24):2630-2633. 10.1056/NEJMe0804182, 18539918.
6. Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med 2011, 124(11):993-996. 10.1016/j.amjmed.2011.08.008, 22017775.
7. Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med 2011, 124(11):1028-1035. 10.1016/j.amjmed.2011.07.011, 22017781.
8. Bramlage P, Binz C, Gitt AK, Krekler M, Plate T, Deeg E, Tschöpe D. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. Cardiovasc Diabetol 2010, 9:53. 10.1186/1475-2840-9-53, 2949713, 20843379.
9. Tschöpe D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Gitt AK. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients-an analysis of the DiaRegis registry. Cardiovasc Diabetol 2011, 10:66. 10.1186/1475-2840-10-66, 3162488, 21756359.
10. Gitt AK, Bramlage P, Binz C, Krekler M, Deeg E, Tschöpe D. [Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany: Results of the DiaRegis registry]. Herz 2012, 37(3):294-300. 10.1007/s00059-012-3611-3, 22476616.
11. Gitt AK, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Tschöpe D. Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry. Eur J Prev Cardiol 2012, 19(4):765-772. 10.1177/1741826711411104, 21628353.
12. Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschöpe D. Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia. Cardiovasc Diabetol 2012, 11:122. 10.1186/1475-2840-11-122, 23039216.
13. Frier BM. Defining hypoglycaemia: what level has clinical relevance?. Diabetologia 2009, 52(1):31-34. 10.1007/s00125-008-1209-3, 19018507.
14. Swinnen SG, Mullins P, Miller M, Hoekstra JB, Holleman F. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. Diabetologia 2009, 52(1):38-41. 10.1007/s00125-008-1147-0, 18806996.
15. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14):977-986. The Diabetes Control and Complications Trial Research Group.
16. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
17. UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50(6):1140-1147. UK Hypoglycaemia Study Group.
18. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. Diabet Med 2006, 23(7):750-756. 10.1111/j.1464-5491.2006.01880.x, 16842479.
19. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, Leese GP. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med 2005, 22(6):749-755. 10.1111/j.1464-5491.2005.01501.x, 15910627.
20. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355(23):2427-2443. 10.1056/NEJMoa066224, 17145742.
21. Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycaemia in adults with Type 1 diabetes. Diabet Med 2008, 25(4):501-504. 10.1111/j.1464-5491.2008.02413.x, 18387080.
22. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28(5):1083-1091. 10.2337/diacare.28.5.1083, 15855571.
23. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52(10):2046-2055. 10.1007/s00125-009-1472-y, 2744824, 19688338.
24. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983, 24(6):404-411.
25. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17(6):467-473. 10.1002/dmrr.235, 11757083.
26. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9(2):194-205. 10.1111/j.1463-1326.2006.00704.x, 17300595.
27. Foley JE, Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 2009, 41(12):905-909. 10.1055/s-0029-1234042, 19705345.
28. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 type 1 diabetic patients. Diabet Med 1991, 8(3):217-222. 10.1111/j.1464-5491.1991.tb01575.x, 1828735.
29. Pedersen-Bjergaard U, Pramming S, Thorsteinsson B. Recall of severe hypoglycaemia and self-estimated state of awareness in type 1 diabetes. Diabetes Metab Res Rev 2003, 19(3):232-240. 10.1002/dmrr.377, 12789657.
30. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Prospective and retrospective recording of severe hypoglycaemia, and assessment of hypoglycaemia awareness in insulin-treated Type 2 diabetes. Diabet Med 2009, 26(12):1306-1308.
31. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363(15):1410-1418. 10.1056/NEJMoa1003795, 20925543.
32. Bott S, Bott U, Berger M, Muhlhauser I. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia 1997, 40(8):926-932. 10.1007/s001250050769, 9267987.
33. The DCCT Research Group Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 1991, 90(4):450-459. The DCCT Research Group.
34. Honkasalo MT, Elonheimo OM, Sane T. Severe hypoglycaemia in drug-treated diabetic patients needs attention: a population-based study. Scand J Prim Health Care 2011, 29(3):165-170. 10.3109/02813432.2011.580090, 3347964, 21675825.
35. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011, 91(3):363-370. 10.1016/j.diabres.2010.12.027, 21251725.
36. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002, 51(3):724-733. 10.2337/diabetes.51.3.724, 11872673.
37. Choudhary P, Amiel SA. Hypoglycaemia: current management and controversies. Postgrad Med J 2011, 87(1026):298-306. 10.1136/pgmj.2008.068197, 21296797.
38. Amiel SA, Maran A, Powrie JK, Umpleby AM, Macdonald IA. Gender differences in counterregulation to hypoglycaemia. Diabetologia 1993, 36(5):460-464. 10.1007/BF00402284, 8314452.
39. Davis SN, Shavers C, Costa F. Gender-related differences in counterregulatory responses to antecedent hypoglycemia in normal humans. J Clin Endocrinol Metab 2000, 85(6):2148-2157. 10.1210/jc.85.6.2148, 10852444.
40. Jones TW, Porter P, Sherwin RS, Davis EA, O'Leary P, Frazer F, Byrne G, Stick S, Tamborlane WV. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998, 338(23):1657-1662. 10.1056/NEJM199806043382303, 9614256.
41. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994, 43(3):403-410. 10.2337/diabetes.43.3.403, 8314012.
42. Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003, 20(12):1016-1021. 10.1046/j.1464-5491.2003.01072.x, 14632703.
43. Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM. Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med 1998, 15(5):398-401. 10.1002/(SICI)1096-9136(199805)15:5<398::AID-DIA595>3.0.CO;2-B, 9609362.